

Remarks

Currently Claims 1-22 are pending.

The specification is amended to include an abstract on a separate page and to recite cross-reference to related applications.

Claims 23-28 are canceled. Claims 4-12, 14, 16-17 and 19-20 are amended herein. The claims are amended to remove multiple dependencies for the purpose of reducing fees. The amendments do not narrow the scope of the claims and no new matter is added.

Notice of Co-Pending Applications

The Examiner is respectfully requested to take note of the following co-pending applications which are commonly owned.

10/362146	2/19/2003
10/433881	6/5/2003
10/433884	6/5/2003
10/468729	8/22/2003
10/473751	10/1/2003
10/473197	9/24/2003
10/473196	9/24/2003
10/473491	9/25/2003
10/487968	2/26/2004
10496358	5/20/2004

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'L. Morgan', with a long, sweeping horizontal line extending to the right.

Lorie Ann Morgan  
Attorney for Applicants  
Registration No. 38,181

Date: 31 March, 2005  
GlaxoSmithKline Inc.  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709  
(919) 483-8222  
fax: (919) 483-7988  
email: Lorie.A.Morgan@GSK.com